Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ ... to take profits on rips here being ...

Gilead Sciences ( (GILD) ) has released its Q3 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market ...

In a report released today, Carter Gould from Barclays maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Companies issue guidance, or expectations of future EPS and revenue, so investors have a sense of how much money a company will make in a future period. The most recent guidance for Gilead ...

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) announced that its investigational HIV-1 inhibitor, lenacapavir, has demonstrated a 96% reduction in HIV infections... ByInvesting.com ...

Gilead Sciences (GILD) is expected to deliver a year ... estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on ...

In the latest trading session, Gilead Sciences (GILD) closed at $88.08 ... The HIV and hepatitis C drugmaker's stock has climbed by 5.87% in the past month, exceeding the Medical sector's loss ...